EyePoint Pharmaceuticals, Inc. (EYPT): Price and Financial Metrics
EYPT Price/Volume Stats
| Current price | $21.28 | 52-week high | $30.99 |
| Prev. close | $22.45 | 52-week low | $4.22 |
| Day low | $20.96 | Volume | 576,500 |
| Day high | $22.30 | Avg. volume | 957,556 |
| 50-day MA | $24.60 | Dividend yield | N/A |
| 200-day MA | $15.77 | Market Cap | 1.06B |
EYPT Stock Price Chart Interactive Chart >
EyePoint Pharmaceuticals, Inc. (EYPT) Company Bio
EyePoint Pharmaceuticals (formerly pSivida Corp.) develops sustained-release drug-delivery products for treating eye diseases in the United States and the United Kingdom. It offers ILUVIEN, an injectable, sustained-release micro-insert for use in treating vision impairment associated with diabetic macular edema; and Retisert for the treatment of posterior uveitis. The company was founded in 1987 and is based in Watertown, Massachusetts.
Latest EYPT News From Around the Web
Below are the latest news stories about EYEPOINT PHARMACEUTICALS INC that investors may wish to consider to help them evaluate EYPT as an investment opportunity.
EyePoint Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceWATERTOWN, Mass., Dec. 20, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, today announced that Jay S. Duker, M.D., President and Chief Executive Officer of EyePoint Pharmaceuticals will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 10, 2024 at 10:30 a.m. PT/1:30 p.m. ET. A webcast and subs |
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)WATERTOWN, Mass., Dec. 18, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). The Company granted stock options to purchase up to an aggregat |
What EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) 194% Share Price Gain Is Not Telling YouEyePoint Pharmaceuticals, Inc. ( NASDAQ:EYPT ) shareholders would be excited to see that the share price has had a... |
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Analysts Just Trimmed Their Revenue Forecasts By 11%Market forces rained on the parade of EyePoint Pharmaceuticals, Inc. ( NASDAQ:EYPT ) shareholders today, when the... |
EyePoint Pharmaceuticals (EYPT) is a Great Momentum Stock: Should You Buy?Does EyePoint Pharmaceuticals (EYPT) have what it takes to be a top stock pick for momentum investors? Let's find out. |
EYPT Price Returns
| 1-mo | -0.93% |
| 3-mo | -2.70% |
| 6-mo | 183.73% |
| 1-year | 338.76% |
| 3-year | 127.11% |
| 5-year | 45.75% |
| YTD | -7.92% |
| 2023 | 560.29% |
| 2022 | -71.41% |
| 2021 | 86.02% |
| 2020 | -57.55% |
| 2019 | -17.99% |
Continue Researching EYPT
Here are a few links from around the web to help you further your research on EyePoint Pharmaceuticals Inc's stock as an investment opportunity:EyePoint Pharmaceuticals Inc (EYPT) Stock Price | Nasdaq
EyePoint Pharmaceuticals Inc (EYPT) Stock Quote, History and News - Yahoo Finance
EyePoint Pharmaceuticals Inc (EYPT) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...